SCHEMBL1508248

SCHEMBL1508248

[O-][S+](c1ccccc1)C(c1ccc(F)cc1)(c1ccc(F)cc1)C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
NR1I2 O75469 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
AGER Q15109 2/20 0.32
MTNR1A P48039 1/20 0.32
KCNN4 O15554 2/20 0.31
RORC P51449 1/20 0.31
CYP2D6 P10635 4/20 0.31
CHRM2 P08172 4/20 0.31
CHRM1 P11229 4/20 0.31
CHRM3 P20309 3/20 0.31
KCNH2 Q12809 3/20 0.31
CHRM4 P08173 2/20 0.31
CHRM5 P08912 2/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1508152 0.76 CYP19A1 (0.34) NPC1RAB9ACYP19A1
SCHEMBL1507934 0.72 KCNN4 (0.39) NFE2L2NPC1RAB9AKCNN4RORC
SCHEMBL1508272 0.69 NR3C1 (0.33) MEN1KMT2ACYP2D6CYP3A4MAPT
SCHEMBL1508031 0.69 NR3C1 (0.34) MEN1KMT2ACYP2D6CYP3A4MAPT
SCHEMBL24277984 0.65 NPC1 (0.40) NPC1RAB9AKCNH2CYP19A1
SCHEMBL1507912 0.65 NPC1 (0.37) KMT2ANPC1RAB9AKCNH2CYP19A1
SCHEMBL1507906 0.65 NR1I2 (0.44) KEAP1NFE2L2NR1I2MEN1KMT2A
SCHEMBL24277980 0.63 CYP19A1 (0.39) MEN1KMT2ANPC1RAB9AKCNH2
SCHEMBL2763170 0.63 KEAP1 (0.70) KEAP1NFE2L2NPC1RAB9ACHRM2
SCHEMBL1508161 0.62 RAB9A (0.39) NPC1RAB9ALMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KEAP1 347/4885NFE2L2 1870/4885NR1I2 3130/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KEAP1 347/4885NFE2L2 1870/4885NR1I2 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.